Physician profile
Guy Christopher Charest
NPI 1770102600
$7,018.10
in general payments reported to CMS, 2019-2025
28 companies · $5,291 in 2025
The $5,291 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,727 · 2025: $5,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,435 · Consulting Fee: $1,375 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,435.11 |
| Consulting Fee | $1,375.00 |
| Education | $207.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,014.02 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $697.28 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $506.04 | 2024-2025 | Zoryve |
| Incyte Corporation | $485.43 | 2024-2025 | Opzelura |
| Abbvie INC. | $429.00 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $317.09 | 2025 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $315.56 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $221.96 | 2024-2025 | |
| Ucb, INC. | $219.70 | 2024-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $195.72 | 2024-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $194.89 | 2025 | Nemluvio, Aklief |
| Mayne Pharma Commercial LLC | $177.57 | 2024-2025 | |
| Lilly USA, LLC | $155.19 | 2024-2025 | Ebglyss, Taltz |
| Strata Skin Sciences, INC. | $154.49 | 2025 | Xtrac |
| Novartis Pharmaceuticals Corporation | $153.74 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $148.92 | 2024 | Vtama |
| Regeneron Pharmaceuticals, INC. | $145.78 | 2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $99.09 | 2025 | Cabtreo, Siliq |
| Leo Pharma INC. | $77.30 | 2025 | Adbry, Anzupgo |
| Pfizer INC. | $73.56 | 2025 | |
| Biofrontera INC. | $53.06 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Medimetriks Pharmaceuticals, INC. | $46.37 | 2025 | Neo-Synalar, Clindacin Etz |
| Botanix Sb INC | $34.92 | 2025 | Sofdra |
| Journey Medical Corporation | $31.64 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.78 | 2025 | Spevigo |
| Fidia Pharma USA INC. | $21.31 | 2025 | |
| Kyowa Kirin, INC. | $18.82 | 2024 | Poteligeo |
| Organon LLC | $5.87 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Charest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.